Patent ID: 8293735

Claim:
A compound which is a thienopyrimidine of formula (I): wherein W represents a thiophene ring; R 1 and R 2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is selected from: (a) a group selected from homopiperazine, piperazine, piperidine, pyrrolidine and azetidine, which group is substituted by one or more substituents selected from C 3 -C 10 cycloalkyl which is unsubstituted or substituted, an O-containing ring which is tetrahydrofuran, tetrahydropyran or oxetane and which is unsubstituted or substituted, —NR′—(CR′ 2 ) r —X wherein each R′ is independently H or C 1 -C 6 alkyl, r is 0 or 1 and X is selected from C 3 -C 10 cycloalkyl which is unsubstituted or substituted, an O-containing ring which is tetrahydrofuran, tetrahydropyran or oxetane and which is unsubstituted or substituted, and a 4-membered saturated N-containing heterocyclic ring which is unsubstituted or substituted, and which group is optionally substituted by one or more further substituents; (b) a 4- to 7-membered saturated N-containing heterocyclic ring which includes 0 or 1 additional heteroatoms selected from N, S and O, the ring being fused to a second ring selected from a 4- to 7-membered saturated N-containing heterocyclic ring as defined above, a 5- to 12-membered unsaturated heterocyclic ring, a 5- to 7-membered saturated O-containing heterocyclic ring, a 3- to 12-membered saturated carbocyclic ring and an unsaturated 5- to 12-membered carbocyclic ring to form a heteropolycyclic ring system, the heteropolycyclic ring system being unsubstituted or substituted; (c) a 4- to 7-membered saturated N-containing heterocyclic ring which includes 0 or 1 additional heteroatoms selected from N, S and O and which further comprises, linking two constituent atoms of the ring, a bridgehead group selected from —(CR′ 2 ) n — and —(CR′ 2 ) r —O—(CR′ 2 ) s — wherein each R′ is as defined above, n is 1, 2 or 3, r is as defined above and s is 0 or 1, the remaining ring positions being unsubstituted or substituted; and (d) a group of formula (IIb): wherein ring B is a 4- to 7-membered saturated N-containing heterocyclic ring which includes 0 or 1 additional heteroatoms selected from N, S and O and ring B′ is a 3- to 12-membered saturated carbocyclic ring, a 5- to 7-membered saturated O-containing heterocyclic ring or a 4- to 7-membered saturated N-containing heterocyclic ring as defined above, each of B and B′ being unsubstituted or substituted; m is 0, 1 or 2; R 3 is H or C 1 -C 6 alkyl; R a is selected from R′, halo, CN, C(O)NR′ 2 , halo(C 1 -C 6 )alkyl, SO 2 R′, SO 2 NR′ 2 , NR′SO 2 R′, NR′C(O)R′, NR′C(O)OR′, NR′C(O)NR′ 2 , OR′ and NR′ 2 , wherein each R′ is independently as defined above; and R 4 is an indole group which is unsubstituted or substituted; or a pharmaceutically acceptable salt thereof.